The UK and US have secured a significant trade agreement that will keep no import taxes on UK drug products being sold in the US market.
Agreement Details of the Accord
Under the terms of the agreement, the UK has agreed to raise spending on medicines through the National Health Service (NHS). This pledge ensures that duties on these vital goods will stay at nothing for a period of 36 months.
This agreement follows previous warnings to dramatically increase duties on branded pharmaceutical imports, with figures floated up to double the cost.
"This deal with the United Kingdom strengthens the global environment for new treatments and brings long-overdue balance to American-British drug exports," a release said.
Economic Significance
Pharmaceuticals constitute one of the Britain's most significant exports to the United States, which is clearly the biggest buyer for major British pharmaceutical firms.
Export figures indicate that in the year to the end of the third quarter, the UK sold drugs valued at £11.1bn to the US. This figure represented a significant portion of all goods exports in that span.
"This agreement protects work, stimulates investment and facilitates the UK to establish itself as a worldwide center for medical research," a minister remarked.
Detailed NHS Changes
The deal entails several key changes from the British government:
- Price Threshold Increase: The UK will lift the price threshold at which it judges new treatments to be prohibitively costly by a quarter.
- Increased NHS Spending: There is a target to raise overall health service expenditure on drugs from 0.3 percent of the national economy to 0.6 percent over the coming ten years.
- Payback Limit: The percentage manufacturers must refund to the NHS to stay within budget will be restricted at fifteen percent. In the past, repayments topped twenty percent.
Broader Context
This agreement follows a ongoing row between the pharmaceutical industry and the British authorities over spending levels and approval rates.
This friction were exacerbated by arguments that US consumers were charged several times more for the same drugs than people in the Britain and the EU.
Recently, several large manufacturing plans in the UK have been halted or abandoned, while major funding commitments have been pledged toward projects in the United States.
One official stated that the NHS must invest a greater share on drugs, noting that its expenditure on drugs had declined as a proportion of its resources over the last ten years.
